FindTrial
Sign In

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, University of California, San Diego, Duke University

Conditions

Cardiometabolic SyndromeDrug InteractionsLDL-Cholersterol LoweringPercutaneous Coronary InterventionPeripheral Endovascular InterventionPrimary PreventionPrimary Prevention of Atherosclerotic Cardiovascular Disease

Phase 3

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Active, not recruitingNCT05739383
Novartis PharmaceuticalsPrimary Prevention of Atherosclerotic Cardiovascular Disease
Start: 2023-03-09End: 2029-04-16Updated: 2026-09-04

Phase 4

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
RecruitingNCT06865885
University of California, San DiegoCardiometabolic Syndrome, Drug Interactions, LDL-Cholersterol Lowering +1
Start: 2025-04-02End: 2027-03-31Target: 100Updated: 2026-07-13
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RecruitingNCT06909565
Duke UniversityPercutaneous Coronary Intervention, Peripheral Endovascular Intervention
Start: 2025-07-23End: 2029-12-01Target: 6000Updated: 2026-09-15

Related Papers

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Cardiovascular Research2024-05-1565 citations